Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes

被引:183
作者
Jiang, R
Schulze, MB
Li, TC
Rifal, N
Stampfer, MJ
Rimm, EB
Hu, FB
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
关键词
D O I
10.2337/diacare.27.8.1991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To evaluate the role of non-HDL cholesterol and apolipoprotein (apo)B, markers of all potentially atherogenic lipoproteins, as predictors of cardiovascular disease (CVD) in comparison with LDL Cholesterol in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - We prospectively followed 746 diabetic men in the Health Professionals' Follow-up Study who were aged 46-81 years and free of CVD or cancer at the time of blood draw in 1993-1994. During 6 years of follow-up, we ascertained 103 incident CVD cases. RESULTS - We used Cox proportional hazard modeling to estimate Lite relative risk (RR) of CVD. After adjustment for age, BMI, and other lifestyle risk factors, the multivariate RR of CVD (the highest versus the lowest quartile) was 2.34 (95% CI 1.26-4.32) for non-HDL cholesterol, 2.31 (1.23-4.35) for apoB, and 1.74 (0.99-3.06) for LDL cholesterol. Comparisons of nested models indicate that non-HDL cholesterol, but not apoB, adds significantly to the prediction of CVD risk beyond LDL cholesterol, The area under the receiver operating characteristic curve was 0.685, 0.691, 0.695, and 0.722 for the CVD risk-prediction model with LDL cholesterol, apoB, non-HDL cholesterol, and total cholesterol-to-HDL Cholesterol ratio (or the non-HDL-Lo-HDL cholesterol ratio), respectively. CONCLUSIONS - Non-HDL cholesterol and apoB are more potent predictors of CVD incidence among diabetic men than LDL cholesterol. Statistically, the ratio Of total to HDL cholesterol is the best predictor of CVD in this cohort of diabetic men.
引用
收藏
页码:1991 / 1997
页数:7
相关论文
共 25 条
[1]   VARIABILITY IN CHOLESTEROL CONTENT AND PHYSICAL-PROPERTIES OF LIPOPROTEINS CONTAINING APOLIPOPROTEIN B-100 [J].
ABATE, N ;
VEGA, GL ;
GRUNDY, SM .
ATHEROSCLEROSIS, 1993, 104 (1-2) :159-171
[2]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[3]  
Criqui Michael H., 1998, American Journal of Medicine, V105, p48S, DOI 10.1016/S0002-9343(98)00212-5
[4]   Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality [J].
Cui, YD ;
Blumenthal, RS ;
Flaws, JA ;
Whiteman, MK ;
Langenberg, P ;
Bachorik, PS ;
Bush, TL .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (11) :1413-1419
[5]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[6]   Serum lipids and incidence of coronary heart disease - Findings from the systolic hypertension in the elderly program (SHEP) [J].
Frost, PH ;
Davis, BR ;
Burlando, AJ ;
Curb, JD ;
Guthrie, GP ;
Isaacsohn, JL ;
WassertheilSmoller, S ;
Wilson, AC ;
Stamler, J .
CIRCULATION, 1996, 94 (10) :2381-2388
[7]   MANAGEMENT OF DYSLIPIDEMIA IN NIDDM [J].
GARG, A ;
GRUNDY, SM .
DIABETES CARE, 1990, 13 (02) :153-169
[8]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[9]   Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy [J].
Grundy, SM .
CIRCULATION, 2002, 106 (20) :2526-2529
[10]  
HARRIS M, 1979, DIABETES, V28, P1039